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Damage-associated endogenous molecules induce innate immune
response, thus making sterile inflammation medically relevant.
Stress-derived extracellular vesicles (stressEVs) released during ox-
idative stress conditions were previously found to activate Toll-
like receptor 4 (TLR4), resulting in expression of a different pattern
of immune response proteins in comparison to lipopolysaccharide
(LPS), underlying the differences between pathogen-induced and
sterile inflammation. Here we report that synergistic activities of
15-lipoxygenase (15-LO) and secreted phospholipase A2 (sPLA2)
are needed for the formation of TLR4 agonists, which were iden-
tified as lysophospholipids (lysoPLs) with oxidized unsaturated acyl
chain. Hydroxy, hydroperoxy, and keto products of 2-arachidonoyl-lysoPI
oxidation by 15-LO were identified by mass spectrometry (MS),
and they activated the same gene pattern as stressEVs. Extracel-
lular PLA2 activity was detected in the synovial fluid from rheuma-
toid arthritis and gout patients. Furthermore, injection of sPLA2
promoted K/BxN serum-induced arthritis in mice, whereby ankle
swelling was partially TLR4 dependent. Results confirm the role of
oxidized lysoPL of stressEVs in sterile inflammation that promotes
chronic diseases. Both 15-LO and sPLA2 enzymes are induced dur-
ing inflammation, which opens the opportunity for therapy with-
out compromising innate immunity against pathogens.
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The innate immune system protects the organism againstpathogens and endogenous damage; however, dysregulated
inflammation may lead to pathology. In infection, tissue damage
caused by acute inflammation is usually limited, but sterile in-
flammation may lead to chronic inflammation and tissue damage
(1). Toll-like receptors (TLRs) and inflammasomes are impor-
tant for recognizing pathogen-associated molecular patterns
(PAMPs). In addition, they can also be activated by endogenous
factors, generally known as damage-associated molecular pat-
terns (DAMPs) that are released as a consequence of trauma
and tissue injury in a broad range of sterile inflammatory dis-
eases (2) such as: ischemia/reperfusion injury (IRI) (3), auto-
immune diseases (4), and aging-related pathologies (5). Sterile
inflammation, which is evoked by tissue damage, is accompanied
by oxidative stress, whereby oxidative damage of biologically
important molecules, such as phospholipids (PLs), DNA, pro-
teins, and other cellular components, can occur and may convert
them to DAMPs, which act as stress-induced signaling molecules
(6–8). According to recent reports, the latter can be released
from cells into the bloodstream by extracellular vesicles (9).
Additionally, several enzymes, among them lipoxygenases and
phospholipases, are induced by stress and contribute to inflam-
mation (10, 11), participating in the formation of DAMPs.
Extracellular vesicles (microvesicles and exosomes; EVs) are
released by cells under normal and stress conditions and have
been detected in all body fluids (12). They can carry proin-
flammatory molecules (13) and as such contribute to disease
progression. We have reported previously that the TLR4/MD-2
complex is activated by the EVs released after oxidative stress
(stressEVs). As inactive EVs were converted into active EVs by
partial oxidation through the Fenton reaction, we concluded that
oxidative stress and oxidation of phospholipids are important for
TLR4 agonist formation (14). Unsaturated fatty acid oxidizing
enzymes like lipoxygenases (LOs) are induced by stress and
contribute to inflammation (15). They are one of two types of
enzymes capable of direct peroxidation of PLs and actually
contribute to the regulation of the inflammatory response as
their oxidized products can exert proinflammatory activity dis-
tinct from the action triggered by bacterial products (16). Also
several phospholipases A2 (especially secreted PLA2 [sPLA2])
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are elevated during inflammation, correlating with severity of the
condition (17). sPLA2 enzymatic activity was detected in several
examined synovial fluids, including rheumatoid, osteoarthritic,
psoriatic, and gouty fluids (18). Duchez et al. (19) observed in-
creased ankle thickness and inflammation in K/BxN serum-
induced arthritis in mice with 12-LO (a mouse ortholog of hu-
man 15-LO) and human sPLA2-IIA expression in comparison to
mice lacking one or both enzymes. In addition, several other
studies have shown that oxidized PLs modulate TLR4 activity
(14, 20–22) and that they can be involved in sterile inflammation-
promoted diseases including atherosclerosis and rheumatoid
arthritis (RA) (23–26). Published data imply that both enzymes
could contribute to TLR4 agonist formation in chronic diseases.
RNA microarray analysis revealed differences between LPS and
stress-derived EV (stressEVs) signaling (14). In this new study
several differently expressed genes involved in immune response
were selected and their expression was compared after activation of
TLR4/MD-2 by LPS, stressEVs, and two putative mouse TLR4/
MD-2 agonists (lipid IVa and paclitaxel). StressEVs and paclitaxel
activated proinflammatory Ccl24 and Il23 cytokine gene expression
and antiinflammatory genes, Tnfaip6 and Socs2. No expression or
only minor expression of these genes was detected after LPS or lipid
IVa stimulation. Additionally, no induction of tolerance in macro-
phages by stressEVs was observed. The results underlie the differ-
ences in classical (pathogen-induced) and sterile inflammation.
Eicosanoid-lysolipids, namely lysophospholipids (lysoPLs) with ox-
idized arachidonoyl acyl chain (e.g., HpETE-LPC, HETE-LPC)
were first determined by Liu et al. (27, 28) in mice and human
tissues and their role as possible signaling molecules was purposed,
but neither their receptor nor signaling pathway had been identi-
fied. Herein we found that 15-LO oxidized 2-arachidonoyl-lysoPLs
are more potent agonists for TLR4/MD-2 than oxidized PLs with
two acyl chains. Decreased 15-LO expression in cells resulted in
release of stressEVs with reduced potency of TLR4 activation
confirming the role of 15-LO as the physiological producer of bi-
ologically active oxidized PL agonists. Additionally, we show that
the formation of lysoPLs depends on the activity of sPLA2s, which
are activated during inflammation. Incubation of different sPLA2s
with 15-LO oxidized synthetic EVs (synEVs) resulted in higher
TLR4 activity. To summarize, we identified and confirmed that
eicosanoid-lysolipids can act as signaling molecules that can be
delivered to other cells as part of EVs and we identified TLR4/
MD-2 as their receptor. Moreover, synovial fluids from patients
with RA and gout exerted sPLA2 activity and injection of sPLA2-
IIA to mice with K/BxN-induced arthritis promoted the ankle
swelling and was partially TLR4 dependent, confirming that both
enzymes are needed for the formation of TLR4 agonists and
contribute to the disease progression. As the formation of TLR4
agonists is enzyme driven, it opens an option of applying specific
inhibitors that could limit the sterile inflammation.
Materials and Methods
More details are provided in SI Appendix.
Isolation and Preparation of EVs. StressEVs were collected after a 50-min to 1-h
stimulation (when cells start to detach) of HEK293 cells with 10 or 12 μM
calcium ionophore A23187 (Sigma) in Hanksʾ balanced salt solution (HBSS)
buffer (Invitrogen) containing 2.5 mM CaCl2. Supernatants were centrifuged
at 800 × g to remove the cells and by two time ultracentrifugation at
100,000 × g (rotor types 50TI or 42.1; Beckman Coulter) stressEVs were iso-
lated. StressEVs were resuspended in phosphate buffered saline (PBS) and
their size was analyzed by dynamic light scattering (DLS; Malvern). Their
concentration was determined by the bicinchonic acid (BCA) assay (Sigma).
SynEVs composed of only PLs were prepared in two ways: First, natural PLs
and lysoPLs were dissolved and mixed in organic solvent in ratios deter-
mined in EVs by Weerheim et al. (29) (SI Appendix, Table S2). Second, 30%
of 1,2-diarachidonoyl-sn-glycero-3-PE (AAPE) and 70% of 1-palmitoyl-2-
oleoyl-glycero-3-PC (POPC) (% weight) were dissolved and mixed in or-
ganic solvent. Organic solvent was evaporated. PLs were hydrated in PBS
at 65 °C for 2 h. The hydrated lipid solution went through two
freeze-thaw-vortex cycles in liquid nitrogen. The synEVs were prepared by
extrusion through 100-nm polycarbonate membranes (Avanti Polar Lipids).
The size of synEVs was confirmed by DLS.
Lipoxygenase 15-LO Oxidation and PLA2 Hydrolysis. Lipoxygenase 15-LO was
immobilized to magnetic beads according to manufacturers’ instructions. A
total of 0.2 mg of 15-LO was bound to 100 μL of beads. According to spectra
at 280 nm, approximately 30% of the added 15-LO bound to the beads.
SynEVs, single PLs, and lysoPLs from natural sources or synthetic 20:4 lysoPI
(all dissolved in organic solvent, evaporated, resuspended and hydrated in
PBS) were incubated with 10 μg of 15-LO in 50 mM borate buffer, pH 9.0, at
room temperature for 10 min. The 15-LO was removed with a magnet and
oxidized compounds were tested for their TLR4 activity or further
hydrolyzed.
SynEVs or oxidized synEVs (composed of 30% AAPE and 70% POPC)
(160 μg/mL) were incubated with porcine sPLA2-IB, recombinant human group
IIA (sPLA2-IIA), or recombinant human group X sPLA2 (sPLA2-X) (both were
prepared as described in refs. 30 and 31) (all 30 μg/mL) or with 5× concen-
trated synovial fluid for 2 h at 37 °C in the presence of 2 mM CaCl2. The
reaction was stopped by the addition of the pan-sPLA2 inhibitor varespladib
(50 μM).
Gene Set Enrichment Analysis. Data that we deposited to Gene Expression
Omnibus (accession number: GSE45234) (14) were obtained from bone
marrow-derived macrophages (BMDM) stimulation with LPS or stressEVs. To
determine which sets of genes are statistically significantly different in ex-
pression between stressEVs- and LPS-stimulated cells we analyzed the
microarray data using gene set enrichment analysis (GSEA) (32). We used
Gene Ontology for gene set annotation. We displayed stressEVs correlated
gene sets with high significance only (false discovery rate [FDR] < 0.001)
using the Enrichment Map visualization tool (33). We manually identified
clusters of gene sets so that there are no shared genes between sets in
different clusters. Moreover, for each cluster we merged all of the gene sets
into a gene list and sorted it according to the default GSEA ranking metric
signal to noise. We display the expression values for the top 15 genes
according to that metric.
Determination of sPLA2 Activity in Synovial Fluid. Synovial fluids from patients
with RA and gout were collected during routine clinical procedures, trans-
ferred into 15-mL tubes, and immediately centrifuged for 10 min at 1,300 × g,
at room temperature. Supernatants were frozen at −80 °C until analysis.
Approval for the use of patient synovial fluid aspirates was obtained after
informed consent which was approved by the Slovene National Medical
Ethics Committee (approval no. 0120-623/2017/6).
Samples were ultracentrifuged at 100,000 × g for 1 h to remove EVs at 3×
concentration. sPLA2 enzymatic activity was assayed using a sensitive fluorometric
assay (34, 35) with sonicated vesicles composed of 1-palmitoyl-2-pyrenedecanoyl-sn-
glycero-3-phosphoglycerol (Invitrogen) on a Safire 2 microplate reader (Tecan). The
specific amount of recombinant sPLA2 was used as standard.
To reduce viscosity, samples were incubated with 10 units/mL of hyal-
uronidase (Sigma) for 1 h at 37 °C. Samples were then concentrated at 3-kDa
cutoff (Amicon Ultra; Millipore) five times and added to the 15-LO
oxidized synEVs.
Arthritis Model. C57BL/6 OlaHsd and B6.129-TLR4tm1Aki (TLR4KO) mice were
used for K/BxN serum transfer-induced arthritis model. Eight-week-old fe-
male mice were used for the experiments. Animals were housed in individ-
ually ventilated cages under specific pathogen-free conditions. Mice were
housed in a 12-h light/dark cycle and given standard mouse chow and water
ad libitum. All animal experiments were performed according to the direc-
tives of the EU 2010/63 and approved by the Administration of the Republic
of Slovenia for Food Safety, Veterinary and Plant Protection of the Ministry
ofAgriculture, Forestry and Foods, Republic of Slovenia (approval no.
U34401-14/2019/8).
For K/BxN serum-induced arthritis (36), we injected mice with 150 μL of
K/BxN serum intraperitoneally (i.p.). On day 2, an additional 90 μL of K/BxN
serum was i.p. administered. To observe additional inflammatory effects of
sPLA2 on arthritis severity and development, 10 μL of recombinant human
sPLA2-IIA (9.5 μg) was injected into the left knee joint using a 30-G needle
(Beckmen). Then mice were monitored for 14 d for arthritis development.
Thickness of knee joints was measured daily using calipers under isoflurane
anesthesia. In wild-type (WT) and TLR4 knockout (KO) mice (both n = 5) both
ankles were measured in WT+sPLA2 (n = 5) and TLR4+sPLA2 (n = 4) mice.
Only left ankles were measured.
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Statistical Analysis. GraphPad Prism 5 was used for preparing the graphs and
performing statistical analysis. In vitro data from two or three independent
experiments are shown. Statistical analysis (SEM and Student’s t test) was
done from pooled data from independent experiments. When values
between WT and KO cells were compared, one-tailed tests were used.
When variance between independent experiments was high, a logarithmic
(natural logarithm - LN) transformation was applied for the data used in
statistical tests. In vivo data showing delta ankle thickness are presented as
A
C
D E
B
Fig. 1. StressEVs and paclitaxel stimulate TLR4/MD-2 differently from LPS and lipid IVa. StressEVs were isolated from HEK293 cells stimulated with A23187.
(A) HEK293T cells were transfected with plasmids for hTLR4, hMD-2/CD14, firefly luciferase under NF-κB promotor and Renilla luciferase for normalization.
HEK293T cells were stimulated with stressEVs (1, 2, or 5 μg/mL) or LPS (2, 5, or 10 ng/mL) for 6 h, 12 h, or 24 h. A dual luciferase test was performed. Negative
controls are transfected but unstimulated cells. (B) The Enrichment Map displays the enriched gene sets in stressEV-stimulated cells as analyzed by GSEA. Red
dots represent increased expression, and the dot size is proportional to the enrichment significance. Related gene sets (with some genes in common) were
manually grouped into clusters and assigned a label. We display only the sets with high significance of differential expression (FDR < 0.001). (C–E) WT or
MyD88 KO macrophages and WT or TRIF KO BMDMs were stimulated for 6 h with paclitaxel (50 μM), lipid IVa (100 ng/mL), stressEVs (10 μg/mL), or with LPS
(2 ng/mL). Il1b, Il23a, and Ccl24 mRNA levels were determined using qPCR. (A) Three independent experiments (indep. exps.) (n = 9); (C and D) three indep.
exps. (n = 3); t test (one-tailed; paired); (E) two indep. exps. (n = 2); t test (one-tailed; paired).
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mean ± SEM. For this experiment, two-way ANOVA was used for
statistical analysis.
Results
LPS and StressEVs Differently Activate Immune Response Genes. Our
previous analysis determined that LPS and stressEVs stimulate
gene expression differently in BMDMs (14), which led us to
propose that distinct signaling pathways are induced by the two
TLR4 agonists. To further elucidate the differences, stressEVs
were isolated after oxidative stress and analyzed for their size
distribution by DLS. The presence of exosomes and micro-
vesicles was determined (SI Appendix, Fig. S1A) and confirmed
in fractions (fr.) collected after density gradient ultracentrifu-
gation by Tsg101 and CD81 markers (mainly in fr. 6 and 7) (SI
Appendix, Fig. S1B). Annexin V was detected in most fractions
(fr. 3 to 8) and calnexin was detected mainly in fr. 8, showing that
different populations of EVs are present. The activation of NF-κB
was tested and it was found that LPS and stressEVs differed in
the strength and the time course of gene expression. LPS was
an inducer of NF-κB (Fig. 1A) with the maximum response
reached after 12 h in comparison to stressEVs where increase in
NF-κB activity was observed even after 24 h. On the other hand,
stressEVs but not LPS were able to activate several other tran-
scription factor (TF) and response elements (such as AP-1, CRE,
SRE, and in a minor way also NF-κB) in a TLR4-independent
manner as well (SI Appendix, Fig. S2 A–C), implying that dif-
ferent molecules present in stressEVs can mediate signaling, thus
showing the heterogeneity of stressEVs.
Several genes that were up-regulated in the microarray anal-
ysis by both LPS and stressEVs (such as Il6 and Il1b) and several
genes that showed significant differences, when induced by
stressEVs in comparison to LPS (ref. 14 and SI Appendix, Fig.
S3), were selected. Il23, Ccl24, Tnfaip6, and Socs2 are involved in
the immune response and by using GSEA analysis they were
evaluated as being a part of clusters of gene sets assigned as the
molecular mediator of immune response, regulation of the re-
sponse to wounding, cytokine response, and others (Fig. 1B).
Along with LPS and stressEVs, lipid IVa, and paclitaxel, both
putative mouse TLR4 agonists (37, 38) were tested for their
effects on gene expression in macrophages. The expressions of
Il1b and Il6 (Fig. 1C and SI Appendix, Fig. S4A) were augmented
by all agonists, whereas Il23, Ccl24 (Fig. 1 D and E), Tnfaip6, and
Socs2 (SI Appendix, Fig. S4 B and C) were more strongly induced
by stressEVs and paclitaxel stimulation than by LPS or lipid IVa.
However, all of the observed agonist-induced changes were de-
pendent on both MyD88 and TRIF pathways (Fig. 1 C–E and SI
Appendix, Fig. S4 A–C), showing the differences in signaling
downstream of these two adapter proteins. Additionally, for
stressEVs we showed that activation of these genes and cytokine
expression were indeed to a large degree TLR4 dependent also
at the cytokine level (Fig. 2 A–H). The addition of stressEVs to
macrophages prevented recognition of TLR4/MD-2 monomer by
MTS510 Ab (Fig. 2I), implying clustering of the receptor. The
results show that structurally different agonists targeting the
same receptor may trigger different responses.
LPS stimulation of monocytes/macrophages makes them
temporarily refractory to the subsequent LPS challenge, a phe-
nomenon called endotoxin tolerance, an important protective
mechanism (39). Interestingly the stimulation of THP-1 macro-
phages by the stressEVs did not induce the tolerance to the
subsequent stressEV (Fig. 2J) or LPS treatment (SI Appendix,
Fig. S4D), pointing to an additional difference that might con-
tribute to the persistent inflammation in chronic diseases.
The 15-Lipoxygenase-Oxidized lysoPLs Are TLR4/MD-2 Ligands. Lip-
oxygenase 15-LO is involved in several chronic diseases from
diabetes to atherosclerosis (40). Its role in the formation of
TLR4/MD-2 ligands has already been suggested (14). PLs share
some structural motifs with LPS, therefore we prepared synEVs
from a mixture of natural PLs that are the constituents of EVs
(29). SynEVs were oxidized by 15-LO, immobilized to magnetic
beads so that the enzyme could be easily removed, and their
activity was tested. 15-LO-oxidized but not untreated synEVs
triggered Il1b and Il6 gene expression (Fig. 3A and SI Appendix,
Fig. S5A). To determine the identity of TLR4/MD-2 activating
molecular species, each PL and lysoPL component was oxidized
separately. Interestingly, only 15-LO-oxidized lysoPLs (lysoPC,
lysoPS, and lysoPE) but not oxidized PLs activated NF-κB
(Fig. 3B) and Il6 and Il1b gene expression in a TLR4-dependent
manner (Fig. 3SI Appendix, Fig. S5B). The PLs and lysoPLs used
were extracted from natural sources and comprise hydrophilic head
groups with diverse acyl chains, which makes it difficult to deter-
mine the structural determinants of an endogenous TLR4 agonist.
To confirm that lysoPLs are indeed TLR4/MD-2 ligands we used
the synthetic 2-arachidonoyl-lysophosphatidylinositol (20:4 lysoPI),
a substrate for 15-LO oxidation. The oxidized products of 20:4
lysoPI were analyzed by mass spectrometry (MS) (SI Appendix, Fig.
S5C), which identified eicosanoid-lysoPL products, namely with
hydroxyl (HETE-LPI product), hydroperoxyl (HpETE-LPI prod-
uct), or keto group (Fig. 3D). This oxidized 20:4 lysoPI activated
cells where gene and cytokine expression was mainly TLR4-
dependent, as shown by a low response in TLR4 KO macro-
phages (Fig. 3 E–K). The MyD88 pathway was involved as well (SI
Appendix, Fig. S5 D and E) and the same genes were activated as by
stressEVs (Fig. 2 A–H). As low cytokine release was observed in
BMDMs after stimulation especially with oxidized 20:4 lysoPI,
dendritic cells, as another type of relevant immune cell in chronic
diseases, were stimulated as well. BMDCs responded with increased
Il-6 expression to both stressEVs and even better to oxidized 20:4
lysoPI (Fig. 3L) in comparison to BMDMs. Furthermore, Il-23 was
detected in supernatants (Fig. 3M) in a TLR4-dependent manner.
Oxidized 20:4 lysoPI-induced TLR4 dimerization was ob-
served by native polyacrylamide gel electrophoresis (PAGE)
though less prominent than with LPS (Fig. 4A). Also a minor
shift in binding of MTS510 Ab to TLR4/MD-2 monomer was
observed (Fig. 4B). Importantly, oxidized 20:4 lysoPI activated
NF-κB TFs in a TLR4-dependent manner, but not other re-
sponse elements, which were activated by stressEVs (SI Appen-
dix, Fig. S6 A and B), further confirming oxidized lysoPLs as the
TLR4-activating ligands.
To further confirm that 15-LO-mediated lysoPI oxidation is
important for the agonistic activity Inhibitor I, a specific inhibitor
of 15-LO, was used. Inhibitor I, when added during 15-LO oxi-
dation, significantly reduced TLR4 activation by oxidized 20:4
lysoPI (Fig. 4C). Additionally, to confirm the role of 15-LO in
the formation of TLR4-active ligands at the cellular level, we
tried to prepare the 15-LO KO HEK293 cells by using CRISPR/
Cas9 technology. We were able to decrease but not fully abolish
15-LO expression (Fig. 4D and SI Appendix, Fig. S7), which was
sufficient to observe reduced activity of isolated stressEVs in
comparison to stressEVs isolated from WT cells (Fig. 4E).
LPS mediates dimerization of the TLR4/MD-2 complex by
interacting with the secondary hydrophobic binding site on the
TLR4 ectodomain involving Phe residues at positions 440 and
463 in hTLR4, and mutants at those sites lost the ability for acti-
vation by LPS (41). TLR4F440A and TLR4F463A mutants expressed
in HEK293T cells were stimulated with LPS or 15-LO-oxidized 20:4
lysoPI. Decreased NF-κB activity was detected by both ligands,
implying that LPS and oxidized lysoPI share the same mechanism of
interaction with TLR4 (Fig. 4F).
Lipoxygenase 15-LO and PLA2 Activities Are Necessary for Endogenous
Agonist Formation. LysoPLs are not present as abundantly as PLs,
so there might be a mechanism to increase their formation.
Several human PLA2 variants exist and, in particular, secreted
PLA2 proteins (sPLA2s) are elevated during inflammation (10).
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PLA2s hydrolyze PLs at the sn-2 position, releasing free fatty
acids and lysoPLs. To test whether PLA2 activity may be im-
portant for providing lysoPLs as the substrate for oxidation by
15-LO, we used AAPE. As PLA2s exhibit increased activity when
the substrate is presented in aggregates rather than in the mo-
nomeric form (42) we prepared synEVs with a diameter of
100 nm (as determined by DLS; SI Appendix, Fig. S1C) con-
taining 30% AAPE and 70% POPC. The synEVs were oxidized
with 15-LO and then hydrolyzed by porcine pancreatic sPLA2-IB
or first hydrolyzed and then oxidized. Oxidation followed by the
hydrolysis of synEVs resulted in higher TLR4/MD-2 activity
(Fig. 5A) than the reverse order and Il1b gene expression
(Fig. 5B). Both enzymes were also needed for the increased Il23
and Il6 gene expressions by synEVs (Fig. 5C and SI Appendix,
Fig. S8A). Along with the porcine pancreatic sPLA2-IB,
recombinant human sPLA2-IIA and sPLA2-X were tested. None
of the sPLA2s alone activated TLR4/MD-2 receptor (SI Ap-
pendix, Fig. S8B), but similarly both human sPLA2s promoted
formation of TLR4 agonists together with 15-LO synergy, which
bound to TLR4/MD-2 receptor (Fig. 5D), resulting in cytokine
expression and Il-6 release (Fig. 5 E and F and SI Appendix, Fig.
S8C), confirming the role of both enzymes in ligand formation.
Recently it was shown that arachidonic acid inhibits TLR4
receptor signaling (43). PLA2 hydrolysis of oxAAPE could also
result in the release of the 15-LO-oxidized arachidonic acid
signaling molecule (15-hydroperoxyeicosatetraenoic acid; 15-
HpETE), however 15-HpETE did not activate TLR4/MD-2 re-
ceptor (SI Appendix, Fig. S9) and activation of TLR4 KO
BMDMs with oxidized and hydrolyzed synEVs was minimal
(Fig. 5 E and F and SI Appendix, Fig. S8C), excluding 15-HpETE
as the major contributor to TLR4-dependent gene expression.
PLA2 Promotes TLR4-Mediated Arthritis. Synovial fluid from RA
patients exerts sPLA2 activity and the presence of several sPLA2
isoforms has been reported (44) that might contribute to ligand
formation (17). Synovial fluid samples from RA and gout pa-
tients were collected and indeed sPLA2 activity was detected
(Fig. 5G). The synovial fluid supernatants were ultracentrifuged
at 100,000 × g to remove the EVs, and added to 15-LO-oxidized
synEVs. No increase in proinflammatory cytokine mRNAs was
detected (SI Appendix, Fig.S10 A and B), but an increase in
antiinflammatory Socs2 and Tnfaip6 mRNA was measured
(Fig. 5H and SI Appendix, Fig. S10C).
Several eicosanoid-lysolipids (oxidized 2-arachidonoyl-lysoPLs),
among them also 15-HETE-lysoPC, have been identified in murine
hepatic tissue and human myocardium (27). Especially the amount
of 15-HETE-lysoPC was increased in lung fibroblasts when they
were treated with calcium ionophore (27). We tried to detect
15-HETE-lysoPLs in synovial fluid by mass spectroscopy. Although
2-arachidonoyl-lysoPLs were detected, we were not able to detect
oxidized 15-HETE-lysoPL products. We only detected com-
pounds that had very similar retention times as the 15-LO-oxidized
A B C D E
F G H I J
Fig. 2. StressEVs activate immune response genes through TLR4/MD-2, but do not induce cell tolerance. (A, C, E, G, and H) WT or TLR4 KO BMDMs were
stimulated for 6 h with stressEVs (10 μg/mL) or LPS (2 ng/mL). Il6, Il23a, Ccl24, Tnfaip6, and Socs2mRNA levels were determined using qPCR. (B, D, and F) WT or
TLR4 KO BMDMs were stimulated for 16 h with LPS (2 ng/mL) or stressEVs (5 μg/mL in F or 10 μg/mL). Il-6 and Ccl24 concentrations in supernatants or Il-23
production in cell lysate were measured by ELISA. ND, not detected. (I) RAW 264.7 cells were stimulated with stressEVs (10 μg/mL) or LPS (1 μg/mL) as a positive
control for 4 h. TLR4/MD-2 dimerization using anti-MTS510-PE Ab was determined by flow cytometry. (J) THP-1 cells were treated for 8 h with low con-
centrations of LPS (10 or 20 ng/mL) or stressEVs (1 or 2 μg/mL), followed by additional LPS (100 ng/mL) or stressEV (10 μg/mL) challenge for 18 h. TNFα levels
were determined using qPCR. (A, C, and E) Four indep. exps. (n = 5); t test (one-tailed; paired); (B and D) two indep. exps. (n = 4); t test (one-tailed; unequal
variance); (F) two indep. exps. (n = 3); (G) three indep. exps. (n = 3); t test (one-tailed; paired); (H) three indep. exps. (n = 4); t test (one-tailed; paired); (J) three
indep. exps. (n = 3). For I, an additional indep. exp. is shown in SI Appendix, Additional data.
Ha et al. PNAS Latest Articles | 5 of 11
IM
M
U
N
O
LO
G
Y
A
N
D
IN
FL
A
M
M
A
TI
O
N
D
ow
nl
oa
de
d 
at
 S
un
gk
yu
nk
w
an
 U
ni
v 
on
 S
ep
te
m
be
r 
25
, 2
02
0 
A B C
D E F
G IH J
K ML
Fig. 3. The 15-LO-oxidized lysoPLs are TLR4-activating ligands. SynEVs composed of PLs and lysoPLs were prepared. (A, C, E, G, I, and K) WT or TLR4 KO
BMDMs were stimulated for 6 h with synEVs or oxidized synEVs (10 μg/mL) in A, singlePLs or oxidized single PLs (10 μg/mL) in C, 20:4 lysoPI or oxidized 20:4
lysoPI (5 μg/mL) in E, G, I, and K, or LPS (2 ng/mL) as a positive control. Il1b, Il6, Il23a, Ccl24, and Tnfaip6 mRNA levels were determined using qPCR. (B)
HEK293T cells expressing hTLR4 and hMD-2/CD14 as well as firefly luciferase under NF-κB promotor and Renilla luciferase for normalization were stimulated
with oxidized single PLs (5 μg/mL) or LPS (10 ng/mL) as a positive control for 24 h. Negative controls are transfected but unstimulated cells. A dual luciferase
test for NF-κB activity was performed. (D) The 15-LO oxidation products of 20:4 lysoPI that were determined by MS. (F, H, and J) WT or TLR4 KO BMDMs were
stimulated for 16 h with LPS (2 ng/mL), 20:4 lysoPI, or oxidized 20:4 lysoPI (10 μg/mL). Il-6 and Ccl24 concentrations in supernatants or Il-23 production in cell
lysate were measured by ELISA. ND, not detected. (L andM) WT or TLR4 KO BMDCs were stimulated for 16 or 8 h to detect Il-6 and Il-23, respectively, with LPS
(2 ng/mL), stressEVs (10 μg/mL), 20:4 lysoPI, or oxidized 20:4 lysoPI (10 μg/mL). Il-6 and Il-23 concentrations in supernatants were measured by ELISA. (A, C, and
K) Three indep. exps. (n = 3); t test (two-tailed; paired or one-tailed; paired for KO); (B) three indep. exps. (n = 6 or 9); t test (two-tailed; unequal var.); n.s., not
significant; (E and G) three indep. exps. (n = 4); t test (two-tailed; paired or one-tailed; paired for KO); (I) two indep. exps. (n = 2); t test (two-tailed; paired or
one-tailed; paired for KO); (F) two indep. exps. (n = 5); t test (two-tailed; unequal var.); (H) two indep. exps. (n = 4); t test (two-tailed; unequal var. or one-
tailed; unequal var. for KO); (J) two indep. exps. (n = 3); t test (two-tailed; unequal var.); and (L andM) two indep. exps. (n = 6); t test (two-tailed; unequal var.
or one-tailed; unequal var. for KO).
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lysoPL standards, so we assume that they are very likely very similar
compounds.
To further confirm the pathophysiological relevance of sPLA2,
K/BxN serum was injected i.p. into WT and TLR4KO mice. No
difference between ankle thickness of WT and TLR4KO mice
was observed when only serum was injected (Fig. 5I). As C57BL/6
mice express no sPLA2-IIA (44), we injected human recombinant
sPLA2-IIA into the left knee on day 2. Injection of sPLA2-IIA
promoted swelling of joints. The ankle thickness was higher in WT
than in TLR4KO mice (Fig. 5I), pointing out the possible role of
TLR4 signaling during sPLA2-promoted arthritis.
Discussion
Sterile inflammation occurs under diverse pathological condi-
tions, such as ischemia/reperfusion or trauma and it also un-
derlies the pathologies of diseases with chronic inflammatory
conditions, including atherosclerosis, autoimmune diseases, aging-
related pathologies, and even cancer (45, 46). The innate immune
signaling pathways (TLRs and inflammasomes are the most ex-
tensively studied) sense infection but also contribute to the sterile
inflammation. Differences in the outcome of both conditions exist,
but the mechanisms have not been fully determined yet.
In this study we showed that stressEVs, released during oxi-
dative stress and representing DAMPs, are a diverse mixture of
EVs according to size and composition. Different distribution of
several markers after gradient ultracentrifugation indicates that
EVs are of different origin and composition. The presence of
annexin V points to similar mechanism of EV release as shown
by Gong et al. (47), whereby activation of necroptosis-involved
mixed lineage kinase-like (MLKL) protein resulted in rapid in-
flux of Ca2+ followed by exposure of PS and annexin V at the cell
surface. As a result, shedding of vesicles from the damaged cell
surface was observed, which serves to preserve the plasma
membrane integrity and support cell survival.
Despite their heterogenicity, we were able to elucidate their
TLR4-activating potential among several other signaling prop-
erties. StressEVs but not LPS activated TLR4-dependent expres-
sion of Ccl24 and Il-23, important in inflammatory autoimmune
diseases such as RA, psoriasis, or in ischemia/reperfusion injury (48,
49), that has already been targeted by therapeutic agents (50). On
the other hand, several antiinflammatory proteins were expressed
during stressEV activation such as Socs2, or Tsg6 (Tnfaip6 gene),
which participate in conversion of macrophages from pro- to an
antiinflammatory type (51). These differences between LPS-mediated
and sterile inflammation result from the activation of different
signaling molecules and transcription factors downstream of MyD88
and TRIF. We observed minor Il-23 mRNA expression after LPS
expression, but no Il-23 cytokine was detected (Figs. 2D, 3H and
3M), although some publications reported that LPS can stimulate Il-
23 production in dendritic cells (52) and also in macrophages at
high concentration (1 μg/mL) (53).
Interestingly, no induction of tolerance was observed after
stressEV stimulation, which makes them different from other
DAMPs (54, 55) and may be a result of activation/interplay be-
tween signaling pathways that stressEVs can induce in a TLR4-
dependent and -independent manner. In RA, the stimulation of
A
B C
D E
F
Fig. 4. Mechanism of oxidized PL formation and TLR4 signaling. (A) Indi-
cated amounts of 20:4 lysoPI or oxidized 20:4 lysoPI were incubated with
TLR4/MD-2 recombinant protein (0.5 μg) and then samples were loaded to
10% native PAGE. The dimerization of TLR4/MD-2 was analyzed by Western
blot. (B) RAW 264.7 cells were stimulated with 20:4 lysoPI, oxidized 20:4
lysoPI (40 μg/mL), or LPS (1 μg/mL) as a positive control for 6 h. TLR4/MD-2
dimerization using anti-MTS510-PE Ab was determined by flow cytometry.
(C and E) HEK293T cells expressing hTLR4, hMD-2/CD14, as well as firefly
luciferase under NF-κB promotor and Renilla luciferase for normalization
were stimulated with 20:4 lysoPI (5 μg/mL), oxidized 20:4 lysoPI (5 μg/mL) in
the presence or absence of Inhibitor I (1 mM) in C, stressEVs WT (5 μg/mL),
stressEVs 15-LO KO (5 μg/mL) in E or LPS (10 ng/mL) as a positive control for
24 h. Dual luciferase tests for NF-κB activity were performed. (D) Western
blot detection of 15-LO and β-actin (loading control) in WT and partial 15-LO
KO HEK293 cells. Asterisk indicates specific band. (F) HEK293T cells express-
ing hMD-2/CD14 and hTLR4WT, hTLR4F440A, or hTLR4F463A as well as luciferase
under NF-κB promotor and Renilla luciferase for normalization were stimu-
lated with 20:4 lysoPI (5 μg/mL), oxidized 20:4 lysoPI (5 μg/mL), or LPS (10 ng/mL)
as a positive control for 24 h. Dual luciferase test for NF-κB activity was
performed. (C) Two indep. exps. (n = 6); t test (two-tailed; unequal var.); (E)
three indep. exps. (n = 6 or 12); t test (two-tailed; unequal var.); (F) three
indep. exps. (n = 8); t test (two-tailed; unequal var.). For B an additional indep.
exp. is shown in SI Appendix, Additional data.
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Fig. 5. Concerted 15-LO and sPLA2 activity is needed for formation of TLR4-activating ligands in synEVs. SynEVs composed of 30% AAPE and 70% POPC were
prepared. (A) HEK293T cells expressing hTLR4 and hMD-2/CD14 or hTLR4 alone as well as firefly luciferase under NF-κB promotor and Renilla luciferase for
normalization were stimulated with synEVs (10 μg/mL), hydrolyzed and oxidized synEVs, oxidized and hydrolyzed synEVs (10 μg/mL), or LPS (10 ng/mL) as a
positive control for 24 h. Negative controls are transfected but unstimulated cells. A dual luciferase test for NF-κB activity was performed. (B, C, E, and H) WT
macrophages (B, C, and H) and WT or TLR4 KO BMDMs (E) were stimulated for 6 h with indicated sPLA2 (1.9 μg/mL) or synovial fluid (SF) (14,7 μL), synEVs
(10 μg/mL), oxidized synEVs (10 μg/mL), indicated oxidized and hydrolyzed synEVs (10 μg/mL) or LPS (2 ng/mL) as a positive control. Il1b, Il6, Il23a, and Socs2
mRNA levels were determined using qPCR. (D) RAW 264.7 cells were stimulated with synEVs, oxidized synEVs, oxidized and hydrolyzed sPLA2-IIA synEVs (40
μg/mL), or LPS (1 μg/mL) as a positive control for 6 h. TLR4/MD-2 dimerization using anti-MTS510-PE Ab was determined by flow cytometry. (F) WT or TLR4 KO
BMDMs were stimulated for 16 h with synEVs (10 μg/mL), oxidized synEVs (10 μg/mL), oxidized and hydrolyzed sPLA2-IIA synEVs (10 μg/mL), or LPS (2 ng/mL) as
a positive control. Il-6 in supernatants was measured by ELISA. (G) PLA2 activity was measured in the SF (ultracentrifuged and concentrated 3×) from RA and
gout patients. (G) Mice (n = 4 to 5 per group) were injected with 150 and 90 μL K/BxN serum on days 0 and 2. On day 2 recombinant human sPLA2-II (9.5 μg)
was injected. The development of arthritis was followed for 14 d. (A) Three indep. exps. (n = 6 or 9); t test (two-tailed; unequal var.); (B) three indep. exps. (n =
3); t test (two-tailed; paired); (C and E) three indep. exps. (n = 4); t test (two-tailed; paired or one-tailed; paired for KO). For D, additional an indep. exp. is
shown in SI Appendix, Additional data. (F) Two indep. exps. (n = 6); t test (two-tailed; unequal var. or one-tailed; unequal var. for KO); (H) two indep. exps.
(n = 2); t test (two-tailed; paired); (I) two-way ANOVA between WT+sPLA2 and TLR4KO+sPLA2 (n = 4 or 5); *P < 0.05, **P < 0.01.
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TLR4 was also shown to be potentiated by cell type-specific in-
tolerance in synovial fibroblasts (56) further contributing to the
disease. Interestingly, paclitaxel, an anticancer drug and an ag-
onist of mouse TLR4/MD-2 (57), induced the same response
pattern as stressEVs, implying it might be possible to design
molecules that activate different immune responses from LPS
although they target the same receptor.
OxPLs have been reported to exert pro- and antiinflammatory
activities, mostly identified by indirect mechanisms of oxPLs
action (58). OxPLs also induce differentiation of macrophages to
Mox type, which is distinct from M1 and M2 types (59). Various
receptors of structurally distinct oxPLs compounds have been
identified such as TLR2, which is not activated by short chain
oxPLs but rather by oxPLs that contain reducible functional
groups on nonfragmented sn-2 acyl chains (60) or caspase-11,
which is activated by short chain 1-palmitoyl-2-(5’-oxo-valeroyl)-sn-
glycero-3-PC (POVPC) or 1-palmitoyl-2-glutaryl-sn-glycero-3-PC
(PGPC) in dendritic cells (61). A contradictory role on TLR4 as a
receptor of oxPLs was partially elucidated by Oskolkova et al. (22).
They showed that oxPLs like 1-palmitoyl-2-(5,6-epoxyisoprostane
E2)-sn-glycero-3-PC (PEIPC) and POVPC inhibit LPS stimulation
at low concentrations, but stimulate cells at high concentrations,
though this effect could also be TLR4 independent. We showed
before that PLs oxidized with the Fenton reaction for 30 min but
not for 24 h activated TLR4 (14). Interestingly, although there are
reports on detection and signaling of oxPLs and oxidized arachi-
donic acid (eicosanoids like prostaglandins, thromboxanes), which is
released from PLs after PLA2 activity, lysoPL products of PLs hy-
drolysis received almost no attention. Herein we focused on oxi-
dized lysoPLs where we identified the structural features of these
TLR4 agonists. We showed that lysoPLs oxidized with 15-LO, in-
dependently of the type of hydrophilic head (PE, PI, PS, or PC),
activated TLR4/MD-2 with higher potency than PLs comprising two
acyl chains. Importantly, the oxidized lysoPI induced the same gene
expression profile as stressEVs. Mass spectrometry identified keto,
hydroxyl (HETE), and hydroperoxyl (HpETE) groups, but whether
all species can act as TLR4 agonists still remains open. Il-6 cytokine
expression from oxidized 20:4 lysoPI-stimulated cells was low
(Fig. 3F) in comparison to LPS, which indicates it is a weak TLR4
agonist, although the local concentration of ox lysoPLs may be high.
Some publications indicate that dendritic cells might respond better
to oxidized PLs than macrophages (61), so BMDCs were stimulated
with either stressEV or oxidized 20:4 lysoPI. DCs released higher
amounts of Il-6 as well as Il-23 to supernatant in response to both
agonists (Fig. 3 L and M) in a TLR4-dependent manner, not only
confirming oxidized 20:4 lysoPI as a TLR4 agonist, but also showing
that DCs may contribute more to innate immune response against
oxidative stress. Additionally, in contrast to lysoPI added in a sus-
pension, when synEVs were oxidized and hydrolyzed, more PL
bound to TLR4/MD-2 receptor (Fig. 5D) with increased expression
of Il-6 (Fig. 5F) although the cells were stimulated with lower
concentration (3 μg/mL of ox lysoPE vs. 10 μg/mL of ox lysoPI).
The results imply that EVs preserve unspecific binding of PLs to
serum proteins and promote their recognition.
Structurally ox lysoPLs are not ideally suited as agonists of
TLR4/MD-2. Most likely several molecules bind into the MD-2
hydrophobic pocket, as it was shown for myristic acid molecules
in the MD-2 crystal structure (62) and for neoseptin (63). Lower
stability of TLR4/MD-2 dimers is expected, probably resulting in
lower activation of signaling pathways. Weaker stimulation and
slower kinetics are favorable characteristics of chronic diseases
and might also be one of the reasons that tolerance was
not observed.
Lipoxygenase 12-LO was detected in EVs isolated from mice
platelets (19). Although we were not able to detect 15-LO inside
stressEVs from human cells we propose that 15-LO activity is
important for stressEV TLR4 agonist activity as stressEV iso-
lated from human cells with impaired 15-LO expression had
significantly lower activity. The 15-LO can oxidize both arachi-
donic acyl chains in AAPE. PLA2 can thus release free oxidized
arachidonic acid (15-HpETE) as well. However, 15-HpETE did
not activate HEK293 cells expressing TLR4/MD-2 receptor.
According to the phospholipid composition in EVs, the frac-
tion of lysoPLs is low (29), so it is reasonable to expect there is a
mechanism that could increase the formation of lysoPLs during
inflammation. PC/lysoPC ratio in the synovial fluid and plasma
of RA patients decreases, which might be due to the increased
PLA2 activity (64) and microvesicles are the preferred substrate
for sPLA2s (65). We confirmed the role of 15-LO and secreted
PLA2 enzymes in the formation of TLR4 agonists. Results imply
that more agonists are formed when PLs are first oxidized and
then hydrolyzed, probably because the oxidized sn-2 fatty acid
moiety protrudes into the aqueous phase resulting in the for-
mation of “whiskers” (66) thus increasing availability to sPLA2.
This result is in agreement with the observation that sPLA2-IIA
has enhanced ability to hydrolyze oxidized low-density lipopro-
tein (LDL) in comparison with unmodified LDL (10).
sPLA2s act on various membranes in the extracellular envi-
ronment, including intact and apoptotic cells, lipoproteins, and
microvesicles, but different isoforms exhibit different abilities to
bind to and hydrolyze target membranes (31). Human and
mouse sPLA2-IIA enzymes are inactive toward intact cells, due
to their poor binding to the PC-rich plasma membrane (31), but
they act on membranes containing negatively charged PLs,
whereas groups V and X sPLA2s bind with high affinity to PC-
rich membranes and efficiently hydrolyze lipoproteins and
plasma membranes of intact cells (31, 67, 68). Intriguingly, while
the antibacterial role of sPLA2-IIA has been well documented
(69), it has been revealed only recently that its endogenous
substrates may be mitochondria released from activated plate-
lets, whereby their hydrolysis leads to exacerbation of inflam-
mation (70). sPLA2 activity was detected in synovial fluid from
patients with RA, gout, psoriasis (18), and especially two iso-
forms are elevated (proinflammatory sPLA2-IIA and anti-
inflammatory sPLA2-V) in synovial fluid from RA patients
(44). Transgenic expression of sPLA2-X resulted in higher in-
duction of cytokines in response to LPS (71), showing its role in
potentiating the immune response although not detected in sy-
novial fluid. In this study we did not determine the identity of the
sPLA2 isoforms in synovial fluid of RA and gout patients, but
given that all three sPLA2s (sPLA2-IB, sPLA2-IIA, and sPLA2-X)
tested could equally contribute to the ligand formation from
synEVs, we suggest that in principle any sPLA2 present in synovial
fluid may contribute to the action and that sPLA2s in synovial fluid
are probably not the only source for TLR4 agonist formation in
sterile inflammation.
Using mass spectrometry, we detected 2-arachidonoyl-lysoPLs
in the synovial fluid, but not oxidized 15-HETE-lysoPL species.
According to the oxidized standards we used (SI Appendix, Tab.
S1), molecules with very similar structure (likely different posi-
tion of double bond) were detected. Given that different lysoPLs
are the source and that oxidized molecules are very unstable
probably reduces the probability of detecting specific molecular
species especially in the extracellular fluid. In support of our data
Liu et al. (27, 28) detected eicosanoid-lysolipids formed by either
COX-2 or 12-LO and iPLA2γ activity in murine hepatic tissue,
murine and human myocardium, as well as in cells exposed to
calcium ionophore. As increased concentrations of 12-HETE-LPC
were detected in serum of old male mice they proposed them as
specific biomarkers for various age-associated diseases (28).
Increased expression of human sPLA2-IIA in mice results in
dermatopathies, similar to psoriasis, but with no significant
inflammatory-cell influx (17) showing the necessity of an addi-
tional mechanism. Concerted activity of 12-LO and sPLA2-IIA
has been shown in the uptake of microparticles by neutrophils
(19). The authors also observed increased ankle thickness and
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inflammation in K/BxN serum-induced arthritis in mice with
both enzymes in comparison to mice lacking one or both en-
zymes in agreement with our observations where injection of
sPLA2-IIA into mice with K/BxN serum-induced arthritis pro-
moted the disease. We additionally showed that sPLA2-IIA
contribution to ankle thickness was partially TLR4 dependent, so
formation of TLR4 agonist might be a relevant process. To
conclude, we revealed the mechanism of endogenous ligand
formation through activity of 15-LO and sPLA2, which contrib-
utes to sterile inflammation in chronic conditions like RA with
differences to classical inflammation on the cytokine level,
thereby giving the option to design specific inhibitors that will
limit sterile inflammation but will not globally affect systemic
innate immunity.
Data Availability. The data that support the graphs within this
paper were deposited to public respository Figshare (72) (DOI:
10.6084/m9.figshare.10008044); more detailed protocols and
materials are available from the corresponding author.
ACKNOWLEDGMENTS. This study was financially supported by the H2020
Marie Sklodowska-Curie Innovative Training Networks project TOLLerant
(grant no. 642157) and the Slovenian Research Agency (research core no. P4-
0176 to R.J. and project no. J3-9257 to M.M.-K). We thank Anja Perčič and
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